Stay updated on Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page
- Check3 days agoChange Detected- Revision: v3.5.5 replaces the previous Revision: v3.5.4 in the page's revision history, indicating the latest build of the page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new revision entry, v3.5.4, was added to the revision history, replacing the previous v3.5.3; this reflects an update to the page's documentation/metadata.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page’s revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a change in the site’s interface or backend version rather than the underlying clinical trial information.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check61 days agoChange DetectedUpdates to the Study Record Dates (e.g., 2026-04-06; 2026-03-23) reflect maintenance of the page's history. The core trial information remains unchanged.SummaryDifference0.3%

- Check68 days agoChange DetectedAdded Adrenal cortex carcinoma as a visible keyword/context reference and linked a Genetics and Rare Diseases Information Center resource. This provides additional background context and a direct external reference related to the study topic.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Adrenocortical Carcinoma Clinical Trial page.